COSMOS Pharmaceutical Corporation
CSMYF · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | $1,011,390,000 | $964,989,000 | $827,697,000 | $755,414,000 |
| % Growth | 4.8% | 16.6% | 9.6% | – |
| Cost of Goods Sold | $798,109,000 | $776,683,000 | $658,979,000 | $603,966,000 |
| Gross Profit | $213,281,000 | $188,306,000 | $168,718,000 | $151,448,000 |
| % Margin | 21.1% | 19.5% | 20.4% | 20% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $116,000 | $128,000 | $127,000 |
| SG&A Expenses | $0 | $1,928,000 | $122,807,000 | $107,756,000 |
| Sales & Mktg Exp. | $0 | $1,812,000 | $1,648,000 | $1,632,000 |
| Other Operating Expenses | $172,877,000 | $154,877,000 | $2,960,000 | $3,066,000 |
| Operating Expenses | $172,877,000 | $156,805,000 | $138,589,000 | $121,651,000 |
| Operating Income | $40,404,000 | $31,501,000 | $30,128,000 | $29,796,000 |
| % Margin | 4% | 3.3% | 3.6% | 3.9% |
| Other Income/Exp. Net | $1,968,000 | $2,218,000 | $2,644,000 | $3,251,000 |
| Pre-Tax Income | $42,372,000 | $33,719,000 | $32,773,000 | $33,048,000 |
| Tax Expense | $11,393,000 | $9,265,000 | $8,975,000 | $9,892,000 |
| Net Income | $30,978,000 | $24,454,000 | $23,797,000 | $23,155,000 |
| % Margin | 3.1% | 2.5% | 2.9% | 3.1% |
| EPS | 390.86 | 308.61 | 600.95 | 584.74 |
| % Growth | 26.7% | -48.6% | 2.8% | – |
| EPS Diluted | 390.86 | 308.61 | 600.95 | 584.74 |
| Weighted Avg Shares Out | 79,257 | 79,240 | 39,599 | 39,599 |
| Weighted Avg Shares Out Dil | 79,257 | 79,240 | 39,599 | 39,599 |
| Supplemental Information | – | – | – | – |
| Interest Income | $48,000 | $44,000 | $47,000 | $52,000 |
| Interest Expense | $254,000 | $99,000 | $51,000 | $52,000 |
| Depreciation & Amortization | $22,229,000 | $19,924,000 | $17,368,000 | $15,110,000 |
| EBITDA | $64,855,000 | $53,742,000 | $50,192,000 | $48,210,000 |
| % Margin | 6.4% | 5.6% | 6.1% | 6.4% |